Physician profile
John J Layden
NPI 1538162235
$1,244.36
in general payments reported to CMS, 2019-2025
13 companies · $14.91 in 2025
The $14.91 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $516 · 2020: $34.77 · 2021: $156 · 2022: $32.83 · 2023: $340 · 2024: $150 · 2025: $14.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $435 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $434.78 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $234.11 | 2019-2024 | Lifevest |
| Abbott Laboratories | $213.18 | 2021-2023 | Cardiomems |
| Baxter Healthcare | $151.06 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Novartis Pharmaceuticals Corporation | $114.55 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $99.67 | 2023 | Camzyos |
| Amgen INC. | $95.25 | 2019-2023 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.54 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $89.93 | 2024 | Uptravi, Opsumit |
| Regeneron Healthcare Solutions, INC. | $50.95 | 2019-2023 | Evkeeza |
| Janssen Pharmaceuticals, INC | $43.31 | 2019-2022 | |
| Boston Scientific Corporation | $28.61 | 2024-2025 | Bodyguardian |
| Sanofi-Aventis U.S. LLC | $18.05 | 2019 | |
| Philips North America LLC | $13.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Layden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.